Inflammation Awakens Dormant Cancer

In a groundbreaking discovery that could reshape our understanding of cancer recurrence, scientists at MIT and the Whitehead Institute have identified a key mechanism that jolts dormant cancer cells back to life. This research, published in the Proceedings of the National Academy of Sciences (PNAS), reveals that inflammation—often triggered by tissue injury from chemotherapy itself—can reactivate “sleeping” cancer cells, enabling them to multiply and potentially cause the disease to return years or even decades after a patient has been declared cancer-free.

The Hidden Threat of Dormant Cancer Cells

Cancer cells are notorious for their relentless drive to grow and divide, but some have developed a particularly insidious survival strategy: dormancy. These rogue cells can break away from the primary tumor, travel through the bloodstream to distant organs, and then remain inactive for extended periods—sometimes for years—like biological landmines waiting to detonate.

This phenomenon, known as metastasis, is especially prevalent in breast cancer. According to the American Cancer Society, distant recurrence rates for early-stage breast cancer range from 10 to 30 percent depending on the subtype. What makes this even more alarming is that metastatic relapse can occur months to decades after initial diagnosis and treatment, accounting for nearly 90 percent of cancer-related deaths—not from the original tumor, but from these secondary growths that emerge in other parts of the body.

As Robert Weinberg, the Daniel K. Ludwig Professor for Cancer Research at MIT and a founding member of the Whitehead Institute, explains, “The inflammation jolts the dormant cancer cells awake. Once awakened, they start multiplying again, seeding new life-threatening tumors in the body.”

Unraveling the Awakening Process

To understand what triggers these dormant cells to reawaken, Weinberg, along with postdoc Jingwei Zhang and their colleagues, conducted a meticulous study using human breast cancer cells injected into mice. By modifying the cancer cells to produce fluorescent proteins, the researchers could track their behavior in real-time within the body.

The team focused on cancer cells that had lodged themselves in lung tissue, confirming their dormant state through specific protein markers: Ki67, ITGB4, and p63. Previous research from the Weinberg Lab had already suggested that inflammation in organ tissue could provoke dormant breast cancer cells to start growing again. This new study took that knowledge further by examining the role of bleomycin—a chemotherapy drug known to cause lung inflammation that is sometimes administered after surgery to lower the risk of cancer recurrence.

tdTomato cancer cells (red) awakened by chemotherapy-induced inflammation, Ki67 (white) marks proliferating cells

In this image, tdTomato cancer cells (red) are seen awakened by chemotherapy-induced inflammation, while Ki67 (white) marks proliferating cells. Image: Jingwei Zhang/Whitehead Institute

The EGFR Signaling Cascade

The study revealed a complex cellular mechanism behind dormancy reversal. The researchers identified a type of immune cell, called M2 macrophages, as key drivers of the awakening process. These macrophages release molecules called epidermal growth factor receptor (EGFR) ligands, which bind to receptors on the surface of dormant cancer cells. This binding activates a cascade of signals that provokes the previously inactive cells to start multiplying rapidly.

However, EGFR signaling is only the initial spark that ignites the fire. As Jingwei Zhang notes, “We found that once dormant cancer cells are awakened, they retain what we call an ‘awakening memory.’ They no longer require ongoing inflammatory signals from the microenvironment to stay active—they remember the awakened state.”

This discovery has significant implications for understanding cancer biology. While scientists now know that signals related to inflammation are necessary to awaken dormant cancer cells, the precise amount of signaling needed remains unclear. As Zhang explains, “This aspect of cancer biology is particularly challenging because multiple signals contribute to the state change in these dormant cells.”

Broader Implications for Cancer Treatment

This research adds a troubling twist to our understanding of chemotherapy’s effects. While chemotherapy is designed to destroy cancer cells, it can also cause tissue inflammation that may inadvertently awaken dormant cells. The finding that common treatments might be contributing to the very problem they’re meant to prevent presents a paradox that oncologists will need to address.

In fact, a study published in Nature notes that metastatic relapse can occur months to decades after initial diagnosis and treatment, highlighting the persistent threat of dormant cancer cells. The discovery that respiratory viruses like influenza and even SARS-CoV-2 can awaken dormant cancer cells in the lungs—similar to chemotherapy-induced inflammation—suggests that inflammation may be a more general mechanism for cancer recurrence than previously thought.

The identification of the “awakening memory” mechanism is particularly significant. Once dormant cancer cells have been activated, they appear to maintain their newfound ability to multiply without continuous inflammatory signals. This suggests that preventing the initial awakening might be more important than trying to control already active cells.

Future Directions in Cancer Research

The Weinberg Lab has already identified one key player in the awakening process, but they acknowledge that understanding the full set of signals involved is far more complex. Their future research will focus on identifying additional factors that contribute to dormancy reversal and exploring how each signal influences the cellular transition from dormancy to active growth.

This research could lead to more effective treatments for patients with metastatic cancers. Understanding these pivotal changes in cancer cell behavior may help scientists develop new strategies to either:

Prevent dormant cells from awakening in the first place
Eliminate dormant cells before they can be reactivated
Keep awakened cells in check once they become active

Putting the Discovery in Perspective

While this study focused on metastatic breast cancer, the mechanisms involved likely apply to other cancer types as well. The concept of tumor dormancy and subsequent reawakening is not unique to breast cancer—it’s a fundamental challenge across oncology. Understanding how inflammation triggers this process represents a significant advance in cancer biology.

The work was supported in part by the MIT Stem Cell Initiative, highlighting the collaborative nature of modern cancer research. The fact that such a prestigious institution is investing resources in understanding dormancy underscores the importance of this area of study for improving patient outcomes.

For cancer patients and survivors, this discovery validates a long-held fear: that the disease might return even after years of being cancer-free. According to the National Cancer Institute, cancer recurrence is a significant concern for millions of survivors, with metastatic disease being the primary cause of cancer-related deaths.

Conclusion

This landmark study by Weinberg, Zhang, and their colleagues provides crucial insights into one of cancer’s most perplexing characteristics: its ability to return long after seeming defeat. By identifying inflammation as a key trigger for awakening dormant cancer cells and uncovering the role of EGFR signaling and awakening memory, the researchers have illuminated a critical pathway that could lead to new therapeutic strategies.

As scientists continue to unravel the complexities of cancer dormancy and reactivation, this research offers hope that one day, the hidden threat of sleeping cancer cells might finally be neutralized—turning those cellular landmines into harmless remnants of a battle already won.